BR112018015143A2 - proteína quimérica recombinante para direcionamento de selectinas - Google Patents

proteína quimérica recombinante para direcionamento de selectinas

Info

Publication number
BR112018015143A2
BR112018015143A2 BR112018015143A BR112018015143A BR112018015143A2 BR 112018015143 A2 BR112018015143 A2 BR 112018015143A2 BR 112018015143 A BR112018015143 A BR 112018015143A BR 112018015143 A BR112018015143 A BR 112018015143A BR 112018015143 A2 BR112018015143 A2 BR 112018015143A2
Authority
BR
Brazil
Prior art keywords
protein
leucine zipper
domain
selectin
chimeric protein
Prior art date
Application number
BR112018015143A
Other languages
English (en)
Portuguese (pt)
Inventor
Lobito Adrian
Koller Christian
Crivellin Federico
Maisano Federico
Bussat Philippe
Cherkaoui Samir
Bettinger Thierry
Original Assignee
Bracco Suisse Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bracco Suisse Sa filed Critical Bracco Suisse Sa
Publication of BR112018015143A2 publication Critical patent/BR112018015143A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/7056—Lectin superfamily, e.g. CD23, CD72
    • C07K14/70564—Selectins, e.g. CD62
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0032—Methine dyes, e.g. cyanine dyes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0056—Peptides, proteins, polyamino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0063—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres
    • A61K49/0069—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres the agent being in a particular physical galenical form
    • A61K49/0076—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres the agent being in a particular physical galenical form dispersion, suspension, e.g. particles in a liquid, colloid, emulsion
    • A61K49/0084—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres the agent being in a particular physical galenical form dispersion, suspension, e.g. particles in a liquid, colloid, emulsion liposome, i.e. bilayered vesicular structure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/085—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier conjugated systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/22—Echographic preparations; Ultrasound imaging preparations ; Optoacoustic imaging preparations
    • A61K49/221—Echographic preparations; Ultrasound imaging preparations ; Optoacoustic imaging preparations characterised by the targeting agent or modifying agent linked to the acoustically-active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/22—Echographic preparations; Ultrasound imaging preparations ; Optoacoustic imaging preparations
    • A61K49/222—Echographic preparations; Ultrasound imaging preparations ; Optoacoustic imaging preparations characterised by a special physical form, e.g. emulsions, liposomes
    • A61K49/223—Microbubbles, hollow microspheres, free gas bubbles, gas microspheres
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1048—Glycosyltransferases (2.4)
    • C12N9/1051—Hexosyltransferases (2.4.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y204/00—Glycosyltransferases (2.4)
    • C12Y204/01—Hexosyltransferases (2.4.1)
    • C12Y204/01039—Steroid N-acetylglucosaminyltransferase (2.4.1.39)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y204/00—Glycosyltransferases (2.4)
    • C12Y204/01—Hexosyltransferases (2.4.1)
    • C12Y204/01068—Glycoprotein 6-alpha-L-fucosyltransferase (2.4.1.68), i.e. FUT8
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/7056—Selectin superfamily, e.g. LAM-1, GlyCAM, ELAM-1, PADGEM
    • G01N2333/70564—Selectins, e.g. CD62

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Radiology & Medical Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Acoustics & Sound (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dispersion Chemistry (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
BR112018015143A 2016-02-09 2017-02-09 proteína quimérica recombinante para direcionamento de selectinas BR112018015143A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP16154868 2016-02-09
PCT/EP2017/052821 WO2017137477A1 (en) 2016-02-09 2017-02-09 A recombinant chimeric protein for selectins targeting

Publications (1)

Publication Number Publication Date
BR112018015143A2 true BR112018015143A2 (pt) 2018-12-18

Family

ID=55435965

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018015143A BR112018015143A2 (pt) 2016-02-09 2017-02-09 proteína quimérica recombinante para direcionamento de selectinas

Country Status (10)

Country Link
US (2) US11370826B2 (enExample)
JP (1) JP6991148B2 (enExample)
KR (1) KR102771920B1 (enExample)
CN (1) CN108699130A (enExample)
AU (1) AU2017218024B2 (enExample)
BR (1) BR112018015143A2 (enExample)
CA (1) CA3011248A1 (enExample)
IL (1) IL260957B2 (enExample)
WO (1) WO2017137477A1 (enExample)
ZA (1) ZA201804657B (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2731524T3 (es) 2012-04-05 2019-11-15 Massachusetts Inst Technology Composiciones inmunoestimuladoras y métodos de uso de las mismas
EP3580231A1 (en) * 2017-02-09 2019-12-18 Bracco Suisse SA Process for the purification of soluble psgl-1 protein variants
JP7654240B2 (ja) * 2017-09-19 2025-04-01 マサチューセッツ インスティテュート オブ テクノロジー キメラ抗原受容体ｔ細胞治療のための組成物およびその使用
WO2019191519A1 (en) * 2018-03-28 2019-10-03 Orionis Biosciences, Inc. Bi-functional proteins and construction thereof
JP7539380B2 (ja) * 2018-12-21 2024-08-23 ブラッコ・スイス・ソシエテ・アノニム リガンドを含むガス充填微小胞
US12453777B2 (en) 2019-03-20 2025-10-28 Massachusetts Institute Of Technology Uses of amphiphiles in immune cell therapy and compositions therefor
US20240108747A1 (en) * 2019-03-21 2024-04-04 Lonza Sales Ag Extracellular vesicle conjugates and uses thereof
WO2021183685A2 (en) * 2020-03-10 2021-09-16 Shaw Gray D Fusion molecules of psgl-1 or tsgl anionic domains to checkpoint-modulating antibodies and other antibodies
US20220184203A1 (en) * 2020-03-31 2022-06-16 Engimata, Inc Immunogenic composition forming a vaccine, and a method for its manufacture
WO2022006564A1 (en) * 2020-07-03 2022-01-06 The Trustees Of Columbia University In The City Of New York Polyfunctional orthogonal protein chimeras

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4276885A (en) 1979-05-04 1981-07-07 Rasor Associates, Inc Ultrasonic image enhancement
US5362476A (en) 1984-10-18 1994-11-08 Board Of Regents, The University Of Texas System Alkyl phosphonate polyazamacrocyclic cheates for MRI
MX174467B (es) 1986-01-23 1994-05-17 Squibb & Sons Inc 1,4,7-triscarboximetil-1,4,7,10-tetraazaciclodo decano substituido en 1 y compuestos analogos
US5021556A (en) 1987-07-22 1991-06-04 Neorx Corporation Method of radiolabeling chelating compounds comprising sulfur atoms with metal radionuclides
IE61591B1 (en) 1987-12-29 1994-11-16 Molecular Biosystems Inc Concentrated stabilized microbubble-type ultrasonic imaging agent and method of production
US5075099A (en) 1988-05-31 1991-12-24 Neorx Corporation Metal radionuclide chelating compounds for improved chelation kinetics
US5364613A (en) 1989-04-07 1994-11-15 Sieving Paul F Polychelants containing macrocyclic chelant moieties
US5118797A (en) 1989-08-28 1992-06-02 E. R. Squibb & Sons, Inc. Rhenium tris dioxime complexes
CA2034042C (en) 1990-01-18 1999-08-17 Adrian D. Nunn Boronic acid adducts of rhenium dioxime and technetium-99m dioxime complexes containing a biochemically active group
IN172208B (enExample) 1990-04-02 1993-05-01 Sint Sa
US5445813A (en) 1992-11-02 1995-08-29 Bracco International B.V. Stable microbubble suspensions as enhancement agents for ultrasound echography
US5556610A (en) 1992-01-24 1996-09-17 Bracco Research S.A. Gas mixtures useful as ultrasound contrast media, contrast agents containing the media and method
US5183653A (en) 1990-04-13 1993-02-02 E. R. Squibb & Sons, Inc. Boronic acid adducts of metal dioxime complexes useful in labelling proteins and other amine-containing compounds
AU636481B2 (en) 1990-05-18 1993-04-29 Bracco International B.V. Polymeric gas or air filled microballoons usable as suspensions in liquid carriers for ultrasonic echography
US5367080A (en) 1990-11-08 1994-11-22 Sterling Winthrop Inc. Complexing agents and targeting radioactive immunoreagents useful in therapeutic and diagnostic imaging compositions and methods
US5965107A (en) 1992-03-13 1999-10-12 Diatide, Inc. Technetium-99m labeled peptides for imaging
US5808091A (en) 1991-10-29 1998-09-15 Bracco International B.V. Rhenium and technetium complexes containing a hypoxia localizing moiety
IL104084A (en) 1992-01-24 1996-09-12 Bracco Int Bv Long-lasting aqueous suspensions of pressure-resistant gas-filled microvesicles their preparation and contrast agents consisting of them
US6277975B1 (en) 1992-10-23 2001-08-21 Genetics Institute, Inc. Fusions of P-selectin ligand protein and polynucleotides encoding same
US5843707A (en) 1992-10-23 1998-12-01 Genetics Institute, Inc. Nucleic acid encoding a novel P-selectin ligand protein
US5608110A (en) 1993-06-15 1997-03-04 Bracco International B.V. Heteroatom-bearing ligands and metal complexes thereof
AU7261994A (en) 1993-07-19 1995-02-20 Resolution Pharmaceuticals Inc. Hydrazino-type radionuclide chelators having an n3s configuration
US5409689A (en) 1993-08-13 1995-04-25 Concat, Ltd. MRI image enhancement using complexes of paramagnetic cations and amine ligands containing a mixture of phosphonate and non-phosphonate pendant arms
US5574140A (en) 1993-09-03 1996-11-12 Resolution Pharmaceutical Inc. Hydrazino-type N2 S2 chelators
US5662885A (en) 1994-07-22 1997-09-02 Resolution Pharmaceuticals Inc. Peptide derived radionuclide chelators
US6333021B1 (en) 1994-11-22 2001-12-25 Bracco Research S.A. Microcapsules, method of making and their use
IL116328A (en) 1994-12-16 1999-09-22 Bracco Research Sa Frozen suspension of gas microbubbles in frozen aqueous carrier for use as contrast agent in ultrasonic imaging
US5886142A (en) 1997-05-20 1999-03-23 Thomas Jefferson University Radiolabeled thrombus imaging agents
US6093382A (en) 1998-05-16 2000-07-25 Bracco Research Usa Inc. Metal complexes derivatized with folate for use in diagnostic and therapeutic applications
IT1315263B1 (it) 1999-12-21 2003-02-03 Bracco Spa Composti chelanti,loro chelati con ioni metallici paramagnetici, loropreparazione ed uso
AU2001247929A1 (en) 2000-03-31 2001-10-15 Genetics Institute, Llc Inhibition of thrombosis by treatment with p-selectin antagonists
US20040167330A1 (en) 2001-07-17 2004-08-26 Ivan Lukes Novel chelating agents and conjugates thereof, their synthesis and use as diagnois and therapeutic agents
ITMI20011518A1 (it) 2001-07-17 2003-01-17 Bracco Imaging Spa Leganti azotati multidentati capaci di complessare ioni metallici e loro uso in diagnostica e in terapia
DE602004029010D1 (de) 2003-02-04 2010-10-21 Bracco Suisse Sa Ultraschall kontrastmittel und verfahren zur erstellung
JP2007516288A (ja) 2003-12-23 2007-06-21 ブラッコ・イメージング・ソシエタ・ペル・アチオニ 金属キレート剤として有用な新規化合物
WO2005105840A2 (en) 2004-03-26 2005-11-10 Five Prime Therapeutics, Inc. Cd40 variants and uses thereof
US9333272B2 (en) 2006-12-11 2016-05-10 Bracco Imaging Spa Fibrin binding peptide conjugates for diagnostic and therapeutic applications
EP2148662A4 (en) 2007-04-20 2014-11-26 Univ Oregon Health & Science ULTRASONIC DISPLAY WITH TARGETED MICROBUMS
CA2806639C (en) 2010-08-09 2020-10-20 Bracco Suisse Sa Targeted gas-filled microvesicles
GB201203071D0 (en) * 2012-02-22 2012-04-04 Ucb Pharma Sa Biological products
EP2639227A1 (en) 2012-03-14 2013-09-18 Bracco Imaging S.p.A A new class of diazepine derivative chelating agents and complexes with paramagnetic metals as MRI contrast agents
JP6227760B2 (ja) 2013-05-30 2017-11-08 ブラッコ・イメージング・ソシエタ・ペル・アチオニＢｒａｃｃｏ Ｉｍａｇｉｎｇ Ｓ．Ｐ．Ａ． 蛍光固形脂質ナノ粒子組成物およびその製法
PT3324938T (pt) 2015-07-20 2021-09-21 Trilogic Pharma Llc Formulações tópicas e tratamentos

Also Published As

Publication number Publication date
JP2019513344A (ja) 2019-05-30
CN108699130A (zh) 2018-10-23
IL260957B2 (en) 2023-11-01
US20190048062A1 (en) 2019-02-14
IL260957A (enExample) 2018-09-20
AU2017218024A1 (en) 2018-08-02
WO2017137477A1 (en) 2017-08-17
ZA201804657B (en) 2019-04-24
JP6991148B2 (ja) 2022-01-12
KR102771920B1 (ko) 2025-02-25
AU2017218024B2 (en) 2020-12-17
US11905323B2 (en) 2024-02-20
IL260957B1 (en) 2023-07-01
CA3011248A1 (en) 2017-08-17
US20220389080A1 (en) 2022-12-08
US11370826B2 (en) 2022-06-28
KR20180104166A (ko) 2018-09-19

Similar Documents

Publication Publication Date Title
BR112018015143A2 (pt) proteína quimérica recombinante para direcionamento de selectinas
BR112014015116A2 (pt) procedimentos de imageamento tomográfico de coerência óptica intracirúrgico de catarata
BR112014032611A2 (pt) disposições de acoplamento para fixação de atuadores de extremidade cirúrgicos a sistemas de acionamento para os mesmos
BR112012027055A8 (pt) agente estabilizante para proteínas farmacêuticas.
BR112015013861A2 (pt) composições e métodos para proteínas de ação prolongada
BR112017009807A2 (pt) métodos e formulações para tratamento de doenças oculares vasculares
BR112017019934A2 (pt) sistemas e métodos para terapia de válvula de coração
BR112014015086A2 (pt) processador de imagem para imageamento tomográfico de coerência óptica intracirúrgico de procedimentos de catarata a laser
BR112015022274A2 (pt) sistema e método de substituição de tornozelo
BR112016020368A2 (pt) proteínas fc multiméricas
BR112016028520A2 (pt) métodos e composições para o tratamento de transtornos com polipeptídeos de folistatina
BR112015017803A2 (pt) interface de paciente birradial
BR112016016658A2 (pt) proteína de fusão de um anticorpo, polinucleotídeo, vetor, célula hospedeira, composição farmacêutica, métodos para produzir uma proteína de fusão e de tratamento de uma doença em um indivíduo e uso da proteína de fusão
BR112018011002A2 (pt) variantes de fgf21
BR112015012739A2 (pt) sistemas e métodos de guia ortopédico
BR112014026162A2 (pt) Proteína de fusão ou variante da mesma, molécula de ácido nucleico, vetor de expressão, célula hospedeira, animal não humano geneticamente modificado, planta geneticamente modificada, agente terapêutico para doenças melhoradas por lactoferrina, composição farmacêutica, e, método para preparar a proteína de fusão ou variante da mesma
MX2016006049A (es) Mimeticos de calcitonina para tratar enfermedades y trastornos.
BR112014012460A2 (pt) proteínas recombinantes e seus usos terapêuticos
BR112015017525A2 (pt) peptídeo modificado, sal de um peptídeo modificado, medicamento, e, métodos para tratar ou aliviar uma doença cardiovascular e para produzir um peptídeo modificado
BR112017020948A2 (pt) composição farmacêutica, método para preparar um agente, método para tratar uma doença ocular e uso de uma proteína de fusão
BR112017008525A2 (pt) proteína de fusão isolada, e, métodos para tratamento ou alívio de um sintoma de uma doença ou distúrbio, para tratamento ou alívio de uma inflamação ou um sintoma de uma doença ou distúrbio inflamatório e para redução do risco de infecção em um indivíduo.
BR112017012928A2 (pt) uso de um ectonucleotídeo pirofosfatase fosfodiesterase (npp1); uso de uma composição farmacêutica; e uso de um snpp1 humano recombinante isolado, fragmento ou proteína de fusão deste
BR112016001782A2 (pt) Proteína de fusão terapêutica
BR112013026661A2 (pt) método de entrega de vacina
BR112018016912A2 (pt) novo antígeno para uso na vacina contra malária

Legal Events

Date Code Title Description
B350 Update of information on the portal [chapter 15.35 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]